BUSCADOR RECOLECTA

This file lists the High Confidence Drivers identified as part of the pan-cancer12 initiative, published in the paper Comprehensive identification of mutational cancer driver genes across 12 tumor types" Scientific Reports 3:2650, 2013, doi:10.1038/srep02650

Genes and pathways affected by expression and copy number changes in tumors across projects and cancer types.

Bioinformatics method to identify individual driver mutations.

This database contains the results of the driver analysis performed by the Cancer Genome Interpreter across 6,792 exomes of a pan-cancer cohort of 28 tumor types. Validated oncogenic mutations are identified according to the state-of-the-art clinical and experimental data, whereas the effect of the mutations of unknown significance is predicted by the OncodriveMUT method.

Mutations, genes and pathways involved in tumorigenesis across 4,623 cancer genomes/exomes from 13 cancer sites. IntOGen-mutations identifies cancer drivers across tumor types. Nature Methods 10, 2013, doi:10.1038/nmeth.2642

CGI drug prescription assigns targeted drugs to a tumor, based on its genomic alterations, according different levels of evidence (from pre-clinical assays to clinical guidelines).

-

The project contains the implementation of the method described in: Wang et al., "Automatic labeling of vascular structures with topological constraints via HMM", MICCAI 2017. We propose a novel graph labeling approach to anatomically label vascular structures of interest. Our algorithm can handle different topologies, like circle, chain and tree. By using coordinate independent geometrical features, it does not require prior global alignment.

Research data from the thesis "Computational Analysis of Audio Recordings and Music Scores for the Description and Discovery of Ottoman-Turkish Makam Music".

The effects on growth performance of supplementation of four different AA combinations in a milk replacer (MR, 25.4% CP and 20.3% fat) based on skimmed milk powder and whey protein concentrate were evaluated in 76 Holstein male calves (3 ± 1.7 d old). The 4 MR were: CTRL with no AA supplementation; PG supplying additional 0.3% Pro and 0.1% Gly; FY supplying additional 0.2% Phe and 0.2% Tyr; KMT providing additional 0.62% Lys, 0.22% Met, and 0.61% Thr. All calves were fed the same milk allowance program and were weaned at 56 d of study. Concentrate intake was limited to minimize interference of potential differences in solid feed intake among treatments. Animals were weighed weekly, intakes recorded daily, and blood samples obtained at 2, 5, and 7 wk of study to determine serum urea and plasma AA concentrations. The file presents data of the backwards selection process to assess the model that fitted better ADG with the study variables (performance, intake, plasma AA balances). Data was collected at Torre Marimon IRTA calf facilities (Caldes de Montbui, Spain) during 2017.